Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.

Liu R, Zhou J, Xia S, Li T.

Urol Int. 2019 Nov 20:1-8. doi: 10.1159/000503906. [Epub ahead of print]

PMID:
31747673
2.

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.

Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Review.

3.

Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.

Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):451-460. doi: 10.1038/s41391-018-0059-4. Epub 2018 Jul 9.

PMID:
29988099
4.

Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.

Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, Zhao D, Niu Y.

BMC Cancer. 2016 Mar 3;16:180. doi: 10.1186/s12885-016-2221-5. Review.

5.

Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.

Wang H, Sun X, Zhao L, Chen X, Zhao J.

J Diabetes Investig. 2016 Jul;7(4):629-36. doi: 10.1111/jdi.12472. Epub 2016 Feb 8.

6.

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

Eur Urol. 2019 Apr;75(4):676-683. doi: 10.1016/j.eururo.2018.11.022. Epub 2018 Nov 26.

PMID:
30497883
7.

Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.

Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E, Oger E.

Eur J Cancer. 2017 May;77:99-108. doi: 10.1016/j.ejca.2017.03.002. Epub 2017 Apr 5.

PMID:
28390298
8.

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.

PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.

9.

Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S.

Eur Urol. 2011 Dec;60(6):1244-50. doi: 10.1016/j.eururo.2011.08.041. Epub 2011 Aug 27.

PMID:
21908097
10.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
11.

[Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].

Merseburger AS, Sedding D, Hüter K.

Urologe A. 2016 Feb;55(2):218-25. doi: 10.1007/s00120-015-0013-1. Review. German.

PMID:
26637324
12.

Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.

Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.

BJU Int. 2016 Aug;118(2):221-9. doi: 10.1111/bju.13203. Epub 2015 Jul 22.

13.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026. Epub 2014 Jan 28.

PMID:
24495466
14.

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.

Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.

PMID:
29037513
15.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

16.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2.

17.

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.

18.

Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.

Eur Urol. 2017 Dec;72(6):920-928. doi: 10.1016/j.eururo.2017.06.036. Epub 2017 Jul 12.

19.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.

Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045. Epub 2012 Feb 1.

20.

No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.

Kao LT, Lin HC, Chung SD, Huang CY.

Asian J Androl. 2017 Jul-Aug;19(4):414-417. doi: 10.4103/1008-682X.179528.

Supplemental Content

Support Center